Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Elaine Flanagan, MD, RhMSUS
Emory University
Peachtree Corners, GA, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Each year, there are new developments in the world of pediatric rheumatology therapy options. The ACR, in collaboration with the FDA, will review major updates on pediatric rheumatology drugs from the past year. Any recent pediatric rheumatology-specific drug safety issues, as well as pediatric drug shortages, will be discussed. Any upcoming information on the COVID-19 vaccine for the pediatric population will be shared. The session will allow for an open dialogue between regulators and rheumatologists regarding these important issues.
Virtual Speaker: Hyun Son, PharmD – Food and Drug Administration
Speaker: Amit Golding, MD, PhD – Food and Drug Administration
